Key facts
- Notable investors include Mirae Science and Technology, Myriad Life Sciences.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for SaerogenBio
- ·The full record, as it builds
Funding rounds
No funding rounds for SaerogenBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SaerogenBio
Operator of a bio-venture company intended for drug discovery and development. The company builds a pipeline of novel therapeutics, including anticancer drugs and treatments for degenerative brain diseases, and concentrates on developing medicines for intractable and unmet medical needs, enabling the healthcare industry to accelerate candidate substance development and bring new drugs close to commercialization.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Ownership
- Privately Held (backing)
SaerogenBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SaerogenBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SaerogenBio in its N-PORT filings yet. We sweep new filings monthly.